TapImmune Announces Phase 2 Ovarian Cancer Trial Study with AstraZeneca/MedImmune and Sloan Kettering Cancer Institute

JACKSONVILLE, Florida, April 21, 2016 /PRNewswire/ – Study to commence Q2 2016 at Sloan Kettering Institute Cancer vaccine and checkpoint inhibitor combination to be evaluated in platinum-resistant ovarian cancer patients TapImmune,Inc. (TPIV), a clinical-stage immunology-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic…

Details

TapImmune to Present at 28th Annual ROTH Conference on March 16, 2016

TapImmune-Corporate-Presentation-2016 JACKSONVILLE, FLORIDA, March 14, 2016 / TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and nucleic acid-based immunotherapeutic vaccines for the treatment of cancer, including metastatic cancer, announced today the company’s Director, Dr. John Bonfiglio will present at the 28th Annual ROTH Conference on March 16, 2016 at…

Details

TapImmune Receives Notice of Allowance on U.S. Patent Claims for PolyStart – Next-Generation T-Cell Vaccine

Proprietary DNA Expression Vector Technology Developed at TapImmune’s Laboratories PolyStart to Move into Clinical Trials and Expand TapImmune‘s Development Pipeline TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and nucleic acid-based immunotherapeutic vaccines for the treatment of cancer, including metastatic cancer, announced today that it has received a Notice…

Details

TapImmune Sponsors 26.2 With DONNA Marathon for Breast Cancer Research and Care

https://markertherapeutics.com/wp-content/uploads/2016/02/Donna-Foundation_295x166.jpg Events & Marathon to take place in Jacksonville, Florida on February 12-14, 2016 JACKSONVILLE, FLORIDA, February 10, 2016 / TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, today announced the Company is a proud sponsor…

Details

TapImmune Granted Fast Track Designation by U.S. Food & Drug Administration for its Lead Vaccine TPIV 200 in the Treatment of Ovarian Cancer

TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, announced today that the U.S. Food & Drug Administration (FDA) has granted Fast Track Designation for its cancer vaccine TPIV 200 in the treatment of ovarian cancer. The…

Details

TapImmune Appoints Frederick G. Wasserman to its Board of Directors

TapImmune Inc. (OTCMKTS: TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, is pleased to announce the appointment of Frederick G. Wasserman to its Board as an Independent Director. Frederick (Rick) is an accomplished Board Director with 35 years…

Details